10-propargyl-10-deazaaminopterin has been researched along with labetalol in 1 studies
| Studies (10-propargyl-10-deazaaminopterin) | Trials (10-propargyl-10-deazaaminopterin) | Recent Studies (post-2010) (10-propargyl-10-deazaaminopterin) | Studies (labetalol) | Trials (labetalol) | Recent Studies (post-2010) (labetalol) |
|---|---|---|---|---|---|
| 119 | 21 | 85 | 1,980 | 450 | 327 |
| Protein | Taxonomy | 10-propargyl-10-deazaaminopterin (IC50) | labetalol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.354 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.01 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.393 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.354 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.521 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.393 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.037 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.607 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.815 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for 10-propargyl-10-deazaaminopterin and labetalol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |